For too long, medical terminology has failed to adequately represent the lived experiences of those it seeks to describe, particularly when it comes to women's health. The renaming of polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) represents a critical step towards rectifying this imbalance and centering patient voices in medical discourse. This victory, announced at the European Congress of Endocrinology in Prague, is the culmination of a 14-year global collaboration, driven by the urgent need for a more accurate and inclusive understanding of the condition that affects an estimated one in eight women.

The term “polycystic” in PCOS has historically been a source of confusion and misdiagnosis, leading to delayed or inadequate care. The new name, PMOS, acknowledges the broader metabolic and endocrine dimensions of the syndrome, recognizing that it extends far beyond the presence of ovarian cysts. This shift is particularly significant for women like Maddy Mavrikis, who shared her story with Guardian Australia, highlighting the frustration of being diagnosed with a condition defined by a symptom she never experienced. Her experience underscores the importance of listening to patients and challenging medical assumptions that perpetuate misinformation.

Moreover, the renaming of PCOS to PMOS addresses the systemic inequities that often plague women's healthcare. Women of color and marginalized communities often face additional barriers to diagnosis and treatment, due to factors such as racial bias in healthcare, lack of access to quality care, and cultural stigmas surrounding reproductive health. By adopting a more comprehensive and accurate name, PMOS has the potential to reduce these disparities by improving awareness, facilitating earlier diagnosis, and promoting more effective treatment strategies for all women, regardless of their background.

Prof. Helena Teede, director of Melbourne’s Monash Centre for Health Research & Implementation, emphasized that the term “polycystic” risked confusion with true ovarian cysts, which can enlarge, bleed and require surgery. “There are no abnormal cysts in PCOS,” she stated, highlighting the importance of moving away from the outdated and misleading terminology. This shift is crucial for ensuring that women receive the accurate information they need to make informed decisions about their health.

The impact of PMOS extends beyond individual health outcomes. By recognizing the metabolic and endocrine dimensions of the syndrome, healthcare providers can better address the long-term health risks associated with the condition, such as diabetes and cardiovascular disease. This holistic approach to healthcare is essential for promoting health equity and reducing the burden of chronic disease among women.